

# Clinical Development Partnerships

---

Releasing the untapped potential  
in cancer drug development



Cancer Research  
Technology





# CDP background and aims

## You

A leading pharmaceutical or biotechnology company.

## Us

Clinical Development Partnerships (CDP) – we bring new life to promising therapies that you have de-prioritised, or 'shelved', for economic or market reasons.

CDP is a joint initiative launched by Cancer Research UK in collaboration with its development and commercialisation company Cancer Research Technology Limited.

## Why use CDP?

By putting your de-prioritised therapies into clinical development with CDP, you can establish which are worth developing further - potentially increasing the number of successful new treatments for cancer patients. CDP is a unique opportunity for your company to maximise its oncology pipeline.

## **Benefits of CDP**

- Early phase clinical development at no upfront cost to your company
- Simple, rapid contractual arrangements and support for knowledge transfer
- The opportunity to work in partnership with Cancer Research UK


## **Our strengths**

- Cancer Research UK is the world's largest independent organisation dedicated to cancer research
- Our Drug Development Office has taken over 100 therapies into first-in-man studies and five of those have subsequently reached the market
- We offer fully integrated project sponsorship, project management and regulatory services

## **Shared risk-reward business model**

- Company retains background intellectual property
- Company has first option to clinical data
- Company and CDP receive appropriate revenue share

## Where we lie on the oncology research pathway



## CDP process and business stages

## What we are looking for

---

### Our primary focus

- Novel targeted small molecules and biological therapeutics
- First in man
- Full pre-clinical toxicology package available
- Clinical material available

### Our secondary focus

- Repurposed agents, improved derivatives, combination studies
- Repeat Phase I studies with redesigned protocol
- Early Phase II (proof of concept)
- Pre-clinical stage projects where *in vivo* efficacy has been demonstrated

## Manufacturing

---

We have state-of-the-art pharmaceutical development and GMP manufacturing facilities

Small molecules are formulated at the Cancer Research UK Formulation Unit

<http://spider.science.strath.ac.uk/sipbs/cancer.htm>

Antibodies, peptides, viruses, plasmid DNA and conjugates are manufactured at our state-of-the-art Biotherapeutics Development Unit

<http://science.cancerresearchuk.org/sci/bdu/>

## Track record and CDP partnerships

---

Five anti-cancer therapies that were taken through exploratory phase clinical trials by the Drug Development Office have subsequently reached the market:

- Temodar (Temozolomide)
- Etopophos (Etoposide Phosphate)
- Lentaron (Formestane)
- Lozoxantrone (Biantrazole)
- Zinecard (Dexrazoxane)

CDP partnerships cover a range of targets and agents:

### **AstraZeneca**

AZD0424 – Tyrosine Kinase Inhibitor

### **Astex Therapeutics**

AT13148 – Protein Kinase B (PKB) Inhibitor

### **GlaxoSmithKline**

GSK1070916A - Aurora Kinase Inhibitor

### **Merck KGaA**

DI-B4 – Anti-CD19 Antibody

### **Immatic**

IMA950 – Peptide Vaccine

### **AstraZeneca**

AZD3965 – Monocarboxylate Transporter I

## What to do next

---

Contact the Clinical Partnerships team:  
[enquiries@clinicalpartnerships.com](mailto:enquiries@clinicalpartnerships.com)

You will be advised on the information required for our New Agents Committee, which peer reviews all our projects.

We look forward to working with you.

For more information and our online enquiry form, visit:

[www.clinicalpartnerships.com](http://www.clinicalpartnerships.com)





*Together we will beat cancer*

Cancer Research UK is a registered charity in England & Wales (1089464)  
and in Scotland (SC041666)